Immunic reveals long-term data supporting potential of MS drug vidofludimus calcium

Immunic Inc. (NASDAQ:IMUX) unveiled compelling long-term data for its experimental oral multiple sclerosis drug, vidofludimus calcium, from an ongoing study. The data, representing approximately 952 cumulative treatment years, demonstrated high efficacy with 92.3% of patients free of 12-week confirmed disability worsening and 92.7% free of 24-week confirmed disability worsening at week 144, alongside a favorable safety profile with no new signals observed over up to 5.5 years. This reinforces prior strong Phase 2 results and positions vidofludimus calcium as a potentially unique oral therapy capable of addressing the critical unmet need of slowing disease progression and preserving neurological function in relapsing-remitting multiple sclerosis.

Analysis

Immunic Inc. (IMUX) has presented compelling long-term data for its experimental multiple sclerosis drug, vidofludimus calcium, reinforcing its clinical potential. The open-label extension study data, covering approximately 952 cumulative treatment years, demonstrates sustained efficacy, with 92.3% of patients remaining free of 12-week confirmed disability worsening and 92.7% free of 24-week worsening at week 144. Critically, the drug appears to address disease progression independent of relapse activity, a key unmet need, as only 13.8% of disability events were attributed to this factor. The safety profile remains favorable over treatment periods of up to 5.5 years, with no new signals and low discontinuation rates, corroborating the strong results from the prior Phase 2 EMPhASIS trial. These findings position vidofludimus calcium as a potentially differentiated oral therapy with neuroprotective and anti-inflammatory mechanisms, strengthening its case for addressing the high-value MS market where slowing disease progression remains a primary therapeutic goal.

Key Decisions for Investors

• The positive long-term efficacy and safety data significantly de-risks the clinical profile of vidofludimus calcium, supporting a bullish outlook on the asset's potential to capture a share of the multiple sclerosis market.
• Investors should monitor for forthcoming details on the design and timeline of pivotal Phase 3 trials, as these will be the next critical catalysts for value realization.
• While the results are strong, it is crucial to consider that the data comes from an open-label extension study, and the asset's ultimate success remains contingent on confirmation in controlled pivotal trials and subsequent regulatory approval.